Filgrastim Use in Post-Lung Transplant Patients with Leukopenia on Valganciclovir
Indications for Filgrastim
- The National Comprehensive Cancer Network recommends filgrastim (G-CSF) at 5 mcg/kg/day subcutaneously when neutrophil counts fall below 500 cells/μL in patients receiving valganciclovir post-lung transplantation 1
Dosing and Administration Protocol
- Standard filgrastim dosing is 5 mcg/kg/day subcutaneously until neutrophil count recovery to normal or near-normal levels, as recommended by the National Comprehensive Cancer Network 2, 3
- The dose may be rounded to the nearest vial size according to institution-defined weight limits, as suggested by the National Comprehensive Cancer Network 4
Risk Factors for Severe Neutropenia
- Advanced age (>65 years) is a risk factor for severe neutropenia in lung transplant recipients on valganciclovir, according to the National Comprehensive Cancer Network 4
- Previous episodes of neutropenia are a risk factor for severe neutropenia in lung transplant recipients on valganciclovir, as reported by the National Comprehensive Cancer Network 5
Management Algorithm for Leukopenia
- For moderate to severe neutropenia (ANC <500 cells/μL), the National Comprehensive Cancer Network recommends initiating filgrastim at 5 mcg/kg/day subcutaneously 1, 2
Clinical Considerations and Caveats
- Pegfilgrastim is not recommended for therapeutic use in this setting due to its long half-life and lack of evidence supporting its use for treatment of established neutropenia, as stated by the National Comprehensive Cancer Network 6, 7
Management of Valganciclovir in Patients with Leukopenia
Assessment and Management of Leukopenia
- For severe neutropenia (ANC <500/mm³), hold valganciclovir until ANC ≥1000/mm³, then resume at the original starting dose if recovery occurs within 7 days, as recommended by the National Comprehensive Cancer Network 8
- If neutropenia persists for more than 7 days, consider reducing valganciclovir dose or switching to alternative therapy, according to the National Comprehensive Cancer Network 8, 9
Dose Adjustment and Alternative Therapies
- Adjust dose based on renal function in addition to hematologic parameters, as suggested by the Infectious Diseases Society of America 10
- Foscarnet is the preferred alternative for patients with severe ganciclovir-induced myelosuppression, as recommended by the National Comprehensive Cancer Network 9, 11
- Maribavir has shown efficacy with lower rates of neutropenia (9.4%) compared to valganciclovir/ganciclovir (33.9%), according to the National Comprehensive Cancer Network 9, 11